New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2013
08:17 EDTCELGAcceleron Pharma and Celgene initiate phase 2 study of ACE-536
Acceleron Pharma announced the initiation of a phase 2 study of its investigational protein therapeutic, ACE-536, to treat anemia in patients with myelodysplastic syndromes, or MDS. MDS are a group of hematologic malignancies of the bone marrow that result in low levels of one or more types of blood cells resulting most commonly in severe and chronic anemia. Acceleron is developing ACE-536 in a global collaboration with Celgene. Acceleron earned a $10M milestone for initiating this phase 2 study and is still eligible to receive development, regulatory and commercial milestones of up to $200M for the ACE-536 program.
News For CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2015
17:08 EDTCELGCelgene announces phase 2 Apremilast data
Subscribe for More Information
April 13, 2015
09:34 EDTCELGActive equity options trading on open
Subscribe for More Information
05:09 EDTCELGCelgene to purchase 14.35M shares of Mesoblast stock for A$3.82 per share
Subscribe for More Information
April 12, 2015
19:33 EDTCELGCelgene takes stake in Australia's Mesoblast, the Australian says
Subscribe for More Information
April 7, 2015
07:24 EDTCELGCelgene Otezla has growing opportunity, says Bernstein
After interviewing small groups of New York City area dermatologists, Bernstein believes that Celgene's psoriasis,treatment, Otezla, has a growing opportunity, due to its oral dosing, convenience, and lack of immunosuppression. The firm quotes doctors as saying that the drug serves as a useful "stepping stone," for patients who might need more intensive therapy, but want to postpone or avoid biologic Bernstein keeps a $158 price target and Outperform rating on Celgene.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use